Abstract
Since it was first introduced 'Fansidar' (pyri-methamine 25 mg, sulfadoxine 500 mg) has been the preferred treatment for uncomplicated chloroquine-resistant Plasmodium falciparum malaria in Thailand. Because many patients at a refugee camp in Thailand did not seem to be responding to therapy 9 patients who received fansidar for P. falciparum infection were followed up with serial parasite counts. In all of them the infection was resistant to fansidar. The results of this study suggest that fansidar resistance is prevalent at this camp and should prompt more exhaustive studies of the epidemiology of fansidar resistance in the area.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
